Vironova Biosafety AB opens its new laboratory for virology studies on Thursday, 10 February 2011.
Vironova Biosafety AB, a subsidiary of the biotechnology company Vironova AB (publ), opens its new laboratory for virus validation studies on Thursday 10 February, 2011. In the newly built premises, located in central Stockholm near the Karolinska Institute, the company will be able to offer the growing Nordic biotech industry the mandatory viral safety studies that are required for the development of new biological drugs (such as recombinant proteins and monoclonal antibodies) and vaccines, in which any component has a human or animal origin.
In connection with the opening, the company invites interested persons to an open house, from 13:00 to about 16:30, where opportunity to a guided tour of the laboratory and a brief presentation will be given of Vironova and Vironova Biosafety business and their future activities.
Registration for the inauguration can be made by phone or by sending an e-mail with your name, phone number and your affiliation/company to invigning@vironova.com.
Visiting address: Gävlegatan 22, entrance A, 3rd floor.
For further information contact:
Mohammed Homman, CEO, Vironova AB (publ), +46 8 702 67 90, ceo@vironova.com or
Bertil Eriksson, CEO, Vironova Biosafety AB, +46 762 477 854, bertil.eriksson@vironova.com.